아시아 태평양 활성 약제 성분(API) 시장 – 2028년까지의 산업 동향 및 예측

보고서 사용자 지정 보고서 사용자 지정 지금 구매 지금 구매 무료 샘플 보고서 무료 샘플 보고서
집 Pharmaceutical Asia Pacific Active Pharmaceutical Ingredient Api Market
TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

아시아 태평양 활성 약제 성분(API) 시장 – 2028년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Apr 2021
  • Asia-Pacific
  • 350 Pages
  • 테이블 수: 419
  • 그림 수: 38
지금 구매 지금 구매

>아시아 태평양 활성 약제 성분(API) 시장, 분자별(소분자, 대분자), 유형(혁신적 활성 약제 성분 , 일반 혁신적 활성 약제 성분), 제조업체 유형(자체 API 제조업체, 상인 API 제조업체), 합성(합성 활성 약제 성분 및 바이오테크 활성 약제 성분), 화학 합성(아세트아미노펜, 아르테미시닌, 삭사글립틴, 염화나트륨, 이부프로펜, 로사르탄 칼륨, 에녹사파린 나트륨, 루피나미드, 나프록센, 타목시펜, 기타), 약물 유형( 처방약, 일반 의약품 ), 용도(임상, 연구), 효능(낮음~중간 효능 활성 약제 성분, 강력~고강력 활성 약제 성분), 치료적 적용(심장학, 중추신경계 및 신경학) 종양학, 정형외과, 내분비학, 폐의학, 위장병학, 신장학, 안과, 기타 치료적 응용 분야), 국가(일본, 중국, 호주, 인도, 한국, 싱가포르, 인도네시아, 태국, 말레이시아, 필리핀, 베트남, 기타 아시아 태평양 지역) 산업 동향 및 2028년까지의 예측

아시아 태평양 활성 약제 성분(API) 시장

시장 분석 및 통찰력 : 아시아 태평양 활성 제약 성분(API) 시장

활성 제약 성분(API) 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년부터 2028년까지의 예측 기간 동안 7.5%의 CAGR로 성장하고 있으며 2028년까지 86,222.48백만 달러에 도달할 것으로 예상된다고 분석했습니다. 다양한 만성 질환의 유병률 증가와 고령화 인구의 증가는 예측 기간 동안 활성 제약 성분(API) 시장 수요를 촉진한 주요 요인입니다.

  • 그리스어로 활성 약리 성분(API)에 대한 전통적 단어는 pharmacon 또는 pharmakon이라고 하며, 마법의 물질이나 약물을 상징합니다. ICH Q7에 설명된 활성 약리 성분은 "약물 제품의 제조에 사용되도록 의도된 물질 또는 물질의 조합으로, 약물 생산에 사용되면 활성 약리 성분이 됩니다. 이러한 물질은 약리학적 활동을 제공하는 데 사용됩니다.

Increase in technological advancements will enhance the capabilities and boost the manufacturing skills of the market players that the manufacturers have to provide APIs in bulk and meet the demand of the consumers which can drive the growth of the active pharmaceutical ingredients (API) market. Availability of sub-standard and counterfeit drugs is acting as a restraint for hampering the demand of the active pharmaceutical ingredients (API) market. Rising investment in research regarding the development of APIs will further increase the growth opportunities for the active pharmaceutical ingredients (API) market. Disruption in the supply chain of APIs during COVID-19 acts challenging for the healthcare providers which may challenge the active pharmaceutical ingredients (API) market.

The active pharmaceutical ingredients (API) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

아시아 태평양 활성 약제 성분(API) 시장

Asia-Pacific Active Pharmaceutical Ingredients (API) Market Scope and Market Size

The active pharmaceutical ingredients (API) market is segmented on the basis of the molecule, type, type of manufacturer, synthesis, chemical synthesis, type of drug, usage, potency and therapeutic application. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of molecule, the active pharmaceutical ingredients (API) market is segmented into small molecule and large molecule. In 2021, small molecule segment is expected to dominate the active pharmaceutical ingredients (API) market due to increasing number of regulatory approval and rising research and development on novel small molecules due to their high penetration power.
  • On the basis of type, the active pharmaceutical ingredients (API) market is segmented into innovative active pharmaceutical ingredients and generic active pharmaceutical ingredients. In 2021, innovative active pharmaceutical ingredients segment is expected to dominate the active pharmaceutical ingredients (API) market because of high cost of innovative APIs in comparison to generic APIs and rising FDA approval for the new molecular entities.
  • On the basis of type of manufacturer, the active pharmaceutical ingredients (API) market is segmented into captive API manufacturer and merchant API manufacturer. In 2021, captive API manufacturer segment is expected to dominate the active pharmaceutical ingredients (API) market due to huge investment by major market players to generate high end manufacturing facilities and easy availability of raw materials.
  • On the basis of synthesis, the active pharmaceutical ingredients (API) market is segmented into synthetic active pharmaceutical ingredients and biotech active pharmaceutical ingredients. In 2021, synthetic active pharmaceutical ingredients segment is expected to dominate the active pharmaceutical ingredients (API) market because of easy protocol for the synthesis of molecules, less stringent regulatory guidelines and in the coming years, many synthetic molecules goes off patent.
  • On the basis of chemical synthesis, the active pharmaceutical ingredients (API) market is segmented into acetaminophen, artemisinin, saxagliptin, sodium chloride, ibuprofen losartan potassium, enoxaparin sodium, rufinamide, naproxen, tamoxifen and others. In 2021, saxagliptin segment is expected to dominate the active pharmaceutical ingredients (API) market due to high cost of the API and rising diabetes cases worldwide.
  • On the basis of type of drug, the active pharmaceutical ingredients (API) market is segmented into prescription drugs and over-the-counter drugs. In 2021, prescription drugs segment is dominating the active pharmaceutical ingredients (API) market because of high cost of the drugs which will increase the APIs and manufacturing cost of the APIs.
  • On the basis of usage, the active pharmaceutical ingredients (API) market is segmented into clinical and research. In 2021, clinical segment is expected to dominate the active pharmaceutical ingredients (API) market because of rising number of diseases which required continuous supply of APIs and raw material.
  • On the basis of potency, the active pharmaceutical ingredients (API) market is segmented into low-to-moderate potency active pharmaceutical ingredients and potent-to-highly potent active pharmaceutical ingredient. In 2021, low-to-moderate potency active pharmaceutical ingredients segment is expected to dominate the active pharmaceutical ingredients (API) market because of their less toxicity and less hazard nature.
  • 치료적 적용을 기준으로, 활성 제약 성분(API) 시장은 심장학, CNS 및 신경학, 종양학 , 정형외과, 내분비학, 폐의학, 위장병학, 신장학, 안과 및 기타 치료적 적용으로 세분화됩니다. 2021년에는 심장병, 색전증 등과 같은 심장 질환의 수가 증가함에 따라 심장학 부문이 활성 제약 성분(API) 시장을 지배할 것으로 예상됩니다.

활성 약제 성분(API) 시장 국가 수준 분석

위에 언급된 국가, 분자, 유형, 제조업체 유형, 합성, 화학 합성, 약물 유형, 사용법, 효능 및 치료적 적용을 기반으로 활성 제약 성분(API) 시장을 분석하고 시장 규모 정보를 제공합니다.

아시아 태평양 활성 제약 성분(API) 시장 보고서에서 다루는 국가는 일본, 중국, 호주, 인도, 한국, 싱가포르, 인도네시아, 태국, 말레이시아, 필리핀, 베트남, 기타 아시아 태평양 지역입니다.

중국은 정부의 API 생산 이니셔티브 덕분에 아시아 태평양 지역 활성 제약 성분(API) 시장을 주도하고 있습니다.   

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 아시아 태평양 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

다양한 만성 질환의 유병률 증가로 인해 API(활성 약제 성분) 시장 성장이 촉진되고 있습니다.

활성 제약 성분(API) 시장은 또한 활성 제약 성분(API) 약물 판매, 활성 제약 성분(API) 기술 발전의 영향, 활성 제약 성분(API) 시장에 대한 지원과 함께 규제 시나리오의 변화와 함께 모든 국가의 활성 제약 성분(API) 산업 성장에 대한 자세한 시장 분석을 제공합니다. 이 데이터는 2010년부터 2019년까지의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 활성 제약 성분(API) 시장 점유율 분석

활성 제약 성분(API) 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세, 기술 수명선 곡선입니다. 제공된 위의 데이터 포인트는 활성 제약 성분(API) 시장과 관련된 회사의 초점에만 관련됩니다.

활성 약제 성분(API)을 거래하는 주요 기업으로는 Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi, GlaxoSmithKline plc., Aarti Industries Limited, Recipharm AB, Jubilant Pharmova Limited, LUPIN, Aurobindo Pharma, AbbVie Inc., AstraZeneca, Alkem Labs, Albemarle Corporation, Saneca Pharmaceuticals, Unichem Laboratories, Neuland Laboratories Ltd., Divi's Laboratories Limited., HIKAL Ltd., Viatris Inc., Merck KGaA, Novo Nordisk A/S, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., BASF SE, Piramal Pharma Solutions 등이 있습니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 별도로 제공합니다. 

또한 전 세계 여러 회사에서 많은 제품 출시와 계약을 체결하면서 활성 약제 성분(API) 시장도 가속화되고 있습니다.

예를 들어,

  • 2019년 12월, AbbVie Inc.는 종양학, 면역학 등 다양한 질병을 타겟으로 하는 신약 발견 연구를 강화하기 위해 Scripps Research와 협력했습니다. 협력 계약에 따라 Scripps Research는 새로운 치료법 개발을 위한 전임상 연구 활동을 수행합니다. 이 협력은 회사가 환자를 위한 새로운 의약품을 개발하는 데 도움이 되었고, 궁극적으로 회사 수익을 증가시켰습니다.

협력, 제품 출시, 사업 확장, 수상 및 인정, 합작 투자 및 시장 참여자의 기타 전략은 API(활성 약제 성분) 시장에서 회사 시장을 강화하고 있으며, 이는 기업이 API(활성 약제 성분)에 대한 제공을 개선하는 데에도 도움이 됩니다.

SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

Sample Image Click on image to enlarge
  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 MOLECULE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET TYPE OF MANUFACTURER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS: COUNTRIES WITH DATA OF IMPORTS AND EXPORTS

4.2 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS: COLOMBIA DATA OF THE ORIGIN COUNTRY OF THE IMPORTS

4.3 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS: COLOMBIA DATA OF THE IMPORTS AND EXPORTS BY MOLECULES IN VALUES AND VOLUMES

5 PIPELINE ANALYSIS

6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: REGULATORY FRAMEWORK

6.1 CURRENT GOODS MANUFACTURING PRACTICES

6.2 REGULATORY REQUIREMENTS FOR REGISTRATION OF API IN THE U.S. AND EU

6.3 REGISTRATION OF API IN THE U.S.

6.4 REGISTRATION OF API IN EUROPE

6.5 REGULATORY REQUIREMENTS IN INDIA

6.6 REGULATORY FRAMEWORK IN CHINA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF VARIOUS CHRONIC DISORDERS

7.1.2 INCREASE IN AGING POPULATION

7.1.3 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING

7.1.4 INCREASING DISEASE AWARENESS AND EDUCATION

7.1.5 PATENT EXPIRY OF BRANDED ACTIVE PHARMACEUTICAL INGREDIENTS (API)

7.2 RESTRAINTS

7.2.1 AVAILABILITY OF SUB-STANDARD AND COUNTERFEIT DRUGS

7.2.2 HIGH MANUFACTURING COST

7.2.3 ADVERSE HEALTH EFFECTS OF EXPOSURE TO ACTIVE PHARMACEUTICAL INGREDIENTS (API)

7.3 OPPORTUNITIES

7.3.1 COLLABORATION AND ACQUISITION AMONG THE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURERS

7.3.2 INCREASING HEALTHCARE EXPENDITURE

7.3.3 RISING INVESTMENT IN RESEARCH REGARDING THE DEVELOPMENT OF ACTIVE PHARMACEUTICAL INGREDIENTS (API)

7.3.4 SOARING NUMBER OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURERS

7.4 CHALLENGES

7.4.1 DISRUPTION IN THE SUPPLY CHAIN OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) DURING COVID-19

7.4.2 LACK OF WORKFORCE IN PHARMA INDUSTRIES

7.4.3 PRODUCT RECALLS

8 IMPACT OF COVID 19 PANDEMIC ON THE ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET

8.1 PRICE IMPACT

8.2 IMPACT ON SUPPLY CHAIN

8.3 IMPACT ON DEMAND

8.4 STRATEGIC DECISIONS FOR MANUFACTURERS

8.5 CONCLUSION

9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE

9.1 OVERVIEW

9.2 SMALL MOLECULE

9.3 LARGE MOLECULE

10 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE

10.1 OVERVIEW

10.2 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

10.3 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

11 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER

11.1 OVERVIEW

11.2 CAPTIVE API MANUFACTURERS

11.3 MERCHANT API MANUFACTURERS

11.3.1 TYPE

11.3.1.1 Merchant Innovative API Manufacturers

11.3.1.2 Merchant Generic API Manufacturers

11.3.2 TYPE OF SYNTHESIS

11.3.2.1 Merchant Synthetic API Manufacturers

11.3.2.2 Merchant Biotech API Manufacturers

12 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS

12.1 OVERVIEW

12.2 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT

12.2.1 INNOVATIVE SYNTHETIC APIS

12.2.2 GENERIC SYNTHETIC APIS

12.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT

12.3.1 TYPE

12.3.1.1 Innovative Biotech APIs

12.3.1.2 Generic Biotech APIs

12.3.2 PRODUCT

12.3.2.1 Monoclonal Antibodies

12.3.2.2 Adalimumab

12.3.2.3 Ustekinumab

12.3.2.4 Secukinumab

12.3.2.5 Cetuximab

12.3.2.6 Daclizumab

12.3.2.7 Omalizumab

12.3.2.8 Vedolizumab

12.3.2.9 Abciximab

12.3.2.10 Efalizumab

12.3.2.11 Others

12.3.2.2 Cytokines

12.3.2.2.1 Interleukin-2

12.3.2.2.2 Interferon Beta-1A

12.3.2.2.3 Interleukin-10

12.3.2.2.4 Interleukin-9

12.3.2.2.5 Erythropoietin

12.3.2.2.6 Others

12.3.2.3 Hormones & Growth Factors

12.3.2.4 Blood Factors

12.3.2.5 Recombinant Vaccines

12.3.2.6 Therapeutic Enzymes

12.3.3 EXPRESSION SYSTEM

12.3.3.1 Mammalian Expression System

12.3.3.2 Yeast Expression System

12.3.3.3 Microbial Expression System

12.3.3.4 Insect Expression System

12.3.3.5 Others Expression System

13 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS

13.1 OVERVIEW

13.2 SAXAGLIPTIN

13.3 ENOXAPARIN SODIUM

13.4 RUFINAMIDE

13.5 TAMOXIFEN

13.6 ARTEMISININ

13.7 LOSARTAN POTASSIUM

13.8 NAPROXEN

13.9 IBUPROFEN

13.1 ACETAMINOPHEN

13.11 SODIUM CHLORIDE

13.12 OTHERS

14 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG

14.1 OVERVIEW

14.2 PRESCRIPTION DRUGS

14.3 OVER-THE-COUNTER

15 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE

15.1 OVERVIEW

15.2 CLINICAL

15.3 RESEARCH

16 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY

16.1 OVERVIEW

16.2 LOW-TO-MODERATE POTENT ACTIVE PHARMACEUTICAL INGREDIENT

16.3 POTENT-TO-HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT

17 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION

17.1 OVERVIEW

17.2 CARDIOLOGY

17.2.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.2.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.3 CNS & NEUROLOGY

17.3.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.3.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.4 ONCOLOGY

17.4.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.4.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.5 GASTROENTEROLOGY

17.5.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.5.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.6 PULMONOLOGY

17.6.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.6.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.7 ENDOCRINOLOGY

17.7.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.7.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.8 NEPHROLOGY

17.8.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.8.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.9 ORTHOPEDIC

17.9.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.9.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.1 OPHTHALMOLOGY

17.10.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.10.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.11 OTHERS

17.11.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.11.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

18 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY REGION

18.1 ASIA-PACIFIC

18.1.1 CHINA

18.1.2 INDIA

18.1.3 JAPAN

18.1.4 AUSTRALIA

18.1.5 SOUTH KOREA

18.1.6 SINGAPORE

18.1.7 MALAYSIA

18.1.8 THAILAND

18.1.9 INDONESIA

18.1.10 PHILIPPINES

18.1.11 VIETNAM

18.1.12 REST OF ASIA-PACIFIC

19 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, COMPANY LANDSCAPE

19.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

20 SWOT ANALYSIS

21 COMPANY PROFILE

21.1 TEVA PHARMECEUTICALS INDUSTRIES LTD.

21.1.1 COMPANY SNAPSHOT

21.1.2 RECENT FINANCIALS

21.1.3 COMPANY SHARE ANALYSIS

21.1.4 PRODUCT PORTFOLIO

21.1.5 RECENT DEVELOPMENT

21.2 PFIZER, INC.

21.2.1 COMPANY SNAPSHOT

21.2.2 REVENUE ANALYSIS

21.2.3 COMPANY SHARE ANALYSIS

21.2.4 PRODUCT PORTFOLIO

21.2.5 RECENT DEVELOPMENTS

21.3 SANOFI

21.3.1 COMPANY SNAPSHOT

21.3.2 REVENUE ANALYSIS

21.3.3 COMPANY SHARE ANALYSIS

21.3.4 PRODUCT PORTFOLIO

21.3.5 RECENT DEVELOPMENTS

21.4 MERCK KGAA

21.4.1 COMPANY SNAPSHOT

21.4.2 REVENUE ANALYSIS

21.4.3 COMPANY SHARE ANALYSIS

21.4.4 PRODUCT PORTFOLIO

21.4.5 RECENT DEVELOPMENT

21.5 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG)

21.5.1 COMPANY SNAPSHOT

21.5.2 REVENUE ANALYSIS

21.5.3 PRODUCT PORTFOLIO

21.5.4 RECENT DEVELOPMENT

21.6 AUROBINDO PHARMA

21.6.1 COMPANY SNAPSHOT

21.6.2 REVENUE ANALYSIS

21.6.3 PRODUCT PORTFOLIO

21.6.4 RECENT DEVELOPMENT

21.7 ALBEMARLE CORPORATION

21.7.1 COMPANY SNAPSHOT

21.7.2 REVENUE ANALYSIS

21.7.3 PRODUCT PORTFOLIO

21.7.4 RECENT DEVELOPMENTS

21.8 ASTRAZENECA

21.8.1 COMPANY SNAPSHOT

21.8.2 REVENUE ANALYSIS

21.8.3 PRODUCT PORTFOLIO

21.8.4 RECENT DEVELOPMENT

21.9 DIVI’S LABORATORIES LIMITED

21.9.1 COMPANY SNAPSHOT

21.9.2 REVENUE ANALYSIS

21.9.3 PRODUCT PORTFOLIO

21.9.4 RECENT DEVELOPMENTS

21.1 DR. REDDY’S LABORATORY LTD.

21.10.1 COMPANY SNAPSHOT

21.10.2 RECENT FINANCIALS

21.10.3 PRODUCT PORTFOLIO

21.10.4 RECENT DEVELOPMENT

21.11 PIRAMAL PHARMA SOLUTIONS

21.11.1 COMPANY SNAPSHOT

21.11.2 PRODUCT PORTFOLIO

21.11.3 RECENT DEVELOPMENTS

21.12 AARTI INDUSTRIES LIMITED

21.12.1 COMPANY SNAPSHOT

21.12.2 REVENUE ANALYSIS

21.12.3 PRODUCT PORTFOLIO

21.12.4 RECENT DEVELOPMENT

21.13 ABBVIE INC

21.13.1 COMPANY SNAPSHOT

21.13.2 REVENUE ANALYSIS

21.13.3 PRODUCT PORTFOLIO

21.13.4 RECENT DEVELOPMENTS

21.14 ALKEM LABS

21.14.1 COMPANY SNAPSHOT

21.14.2 REVENUE ANALYSIS

21.14.3 PRODUCT PORTFOLIO

21.14.4 RECENT DEVELOPMENTS

21.15 ALEMBIC PHARMACEUTICALS LIMITED

21.15.1 COMPANY SNAPSHOT

21.15.2 REVENUE ANALYSIS

21.15.3 PRODUCT PORTFOLIO

21.15.4 RECENT DEVELOPMENTS

21.16 BASF SE

21.16.1 COMPANY SNAPSHOT

21.16.2 RECENT FINANCIALS

21.16.3 PRODUCT PORTFOLIO

21.16.4 RECENT DEVELOPMENT

21.17 CIPLA INC.

21.17.1 COMPANY SNAPSHOT

21.17.2 RECENT FINANCIALS

21.17.3 PRODUCT PORTFOLIO

21.17.4 RECENT DEVELOPMENTS

21.18 CORDENPHARMA INTERNATIONAL

21.18.1 COMPANY SNAPSHOT

21.18.2 PRODUCT PORTFOLIO

21.18.3 RECENT DEVELOPMENTS

21.19 GLAXOSMITHKLINE PLC

21.19.1 COMPANY SNAPSHOT

21.19.2 REVENUE FINANCIALS

21.19.3 PRODUCT PORTFOLIO

21.19.4 RECENT DEVELOPMENT

21.2 HIKAL LTD.

21.20.1 COMPANY SNAPSHOT

21.20.2 REVENUE ANALYSIS

21.20.3 PRODUCT PORTFOLIO

21.20.4 RECENT DEVELOPMENTS

21.21 JUBILANT LIFE SCIENCES LIMITED

21.21.1 COMPANY SNAPSHOT

21.21.2 REVENUE ANALYSIS

21.21.3 PRODUCT PORTFOLIO

21.21.4 RECENT DEVELOPMENT

21.22 LUPIN

21.22.1 COMPANY SNAPSHOT

21.22.2 REVENUE ANALYSIS

21.22.3 PRODUCT PORTFOLIO

21.22.4 RECENT DEVELOPMENTS

21.23 MINAKIM

21.23.1 COMPANY SNAPSHOT

21.23.2 PRODUCT PORTFOLIO

21.23.3 RECENT DEVELOPMENTS

21.24 NEULAND LABORATORIES LTD.

21.24.1 COMPANY SNAPSHOT

21.24.2 REVENUE ANALYSIS

21.24.3 PRODUCT PORTFOLIO

21.24.4 RECENT DEVELOPMENTS

21.25 NOVO NORDISK A/S

21.25.1 COMPANY SNAPSHOT

21.25.2 REVENUE ANALYSIS

21.25.3 PRODUCT PORTFOLIO

21.25.4 RECENT DEVELOPMENT

21.26 RECIPHARM AB

21.26.1 COMPANY SNAPSHOT

21.26.2 REVENUE ANALYSIS

21.26.3 PRODUCT PORTFOLIO

21.26.4 RECENT DEVELOPMENTS

21.27 SANECA PHARMACEUTICALS

21.27.1 COMPANY SNAPSHOT

21.27.2 PRODUCT PORTFOLIO

21.27.3 RECENT DEVELOPMENTS

21.28 SUN PHARMACEUTICAL INDUSTRIES LTD.

21.28.1 COMPANY SNAPSHOT

21.28.2 REVENUE ANALYSIS

21.28.3 PRODUCT PORTFOLIO

21.28.4 RECENT DEVELOPMENTS

21.29 UNICHEM LABORATORIES

21.29.1 COMPANY SNAPSHOT

21.29.2 REVENUE ANALYSIS

21.29.3 PRODUCT PORTFOLIO

21.29.4 RECENT DEVELOPMENTS

21.3 VIATRIS INC.

21.30.1 COMPANY SNAPSHOT

21.30.2 PRODUCT PORTFOLIO

21.30.3 RECENT DEVELOPMENTS

22 QUESTIONNAIRE

23 RELATED REPORTS

표 목록

TABLE 1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, PIPELINE ANALYSIS

TABLE 2 DIFFERENCE BETWEEN THE U.S. AND EU FOR THE REGISTRATION PROCESS

TABLE 3 DIFFERENCE BETWEEN THE U.S. AND EU FOR THE ADMINISTRATIVE REQUIREMENTS

TABLE 4 AGE DISTRIBUTION OF THE U.K. POPULATION (FROM 1976 TO 2046)

TABLE 5 WORLD –WIDE IMPACT OF COVID-19 ON THE PHARMACEUTICAL SECTOR

TABLE 6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 7 ASIA-PACIFIC SMALL MOLECULE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 8 ASIA-PACIFIC LARGE MOLECULE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 10 ASIA-PACIFIC INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 11 ASIA-PACIFIC GENERIC ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 12 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURERS, 2017-2028 (USD MILLION)

TABLE 13 ASIA-PACIFIC CAPTIVE API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 14 ASIA-PACIFIC MERCHANT API MANUFACTURER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET , BY REGION, 2017-2028 (USD MILLION)

TABLE 15 ASIA-PACIFIC TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 16 ASIA-PACIFIC TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 17 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 18 ASIA-PACIFIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 19 ASIA-PACIFIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 20 ASIA-PACIFIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 21 ASIA-PACIFIC TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 22 ASIA-PACIFIC PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 23 ASIA-PACIFIC MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 24 ASIA-PACIFIC CYTOKINESPRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 25 ASIA-PACIFIC EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 26 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (USD MILLION)

TABLE 27 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (UNITS)

TABLE 28 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (ASP)

TABLE 29 ASIA-PACIFIC SAXAGLIPTIN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, REGION, 2017-2028 (USD MILLION)

TABLE 30 ASIA-PACIFIC ENOXAPARIN SODIUM IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 31 ASIA-PACIFIC RUFINAMIDE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 32 ASIA-PACIFIC TAMOXIFEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 33 ASIA-PACIFIC ARTEMISININ IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 34 ASIA-PACIFIC LOSARTAN POTASSIUM IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 35 ASIA-PACIFIC NAPROXEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 36 ASIA-PACIFIC IBUPROFEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 37 ASIA-PACIFIC ACETAMINOPHEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 38 ASIA-PACIFIC SODIUM CHLORIDE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 39 ASIA-PACIFIC OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 40 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2019-2028 (USD MILLION)

TABLE 41 ASIA-PACIFIC PRESCRIPTION DRUGS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 42 ASIA-PACIFIC OVER-THE-COUNTER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 43 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 44 ASIA-PACIFIC CLINICAL IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 45 ASIA-PACIFIC OVER-THE-COUNTER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 46 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 47 ASIA-PACIFIC LOW-TO-MODERATE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 48 ASIA-PACIFIC POTENT-TO-HIGHLY POTENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 49 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 50 ASIA-PACIFIC CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 51 ASIA-PACIFIC CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 52 ASIA-PACIFIC CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 53 ASIA-PACIFIC CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 54 ASIA-PACIFIC ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 55 ASIA-PACIFIC ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 56 ASIA-PACIFIC GASTROENTEROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 57 ASIA-PACIFIC GASTROENTEROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 58 ASIA-PACIFIC PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 59 ASIA-PACIFIC PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 60 ASIA-PACIFIC ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 61 ASIA-PACIFIC ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 62 ASIA-PACIFIC NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 63 ASIA-PACIFIC NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 64 ASIA-PACIFIC ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 65 ASIA-PACIFIC ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 66 ASIA-PACIFIC OPHTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 67 ASIA-PACIFIC OPHTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 68 ASIA-PACIFIC OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 69 ASIA-PACIFIC OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 70 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY COUNTRY, 2018-2028 (USD MILLION)

TABLE 71 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 72 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 73 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 74 ASIA-PACIFIC TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 75 ASIA-PACIFIC TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 76 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 77 ASIA-PACIFIC SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 78 ASIA-PACIFIC TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 79 ASIA-PACIFIC PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 80 ASIA-PACIFIC MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 81 ASIA-PACIFIC CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 82 ASIA-PACIFIC EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 83 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 84 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 85 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 86 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 87 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 88 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 89 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 90 ASIA-PACIFIC CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 91 ASIA-PACIFIC CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 92 ASIA-PACIFIC ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 93 ASIA-PACIFIC GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 94 ASIA-PACIFIC PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 95 ASIA-PACIFIC ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 96 ASIA-PACIFIC NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 97 ASIA-PACIFIC ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 98 ASIA-PACIFIC OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 99 ASIA-PACIFIC OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 100 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 101 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 102 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 103 CHINA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 104 CHINA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 105 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 106 CHINA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 107 CHINA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 108 CHINA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 109 CHINA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 110 CHINA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 111 CHINA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 112 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 113 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 114 UDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 115 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 116 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 117 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 118 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 119 CHINA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 120 CHINA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 121 CHINA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 122 CHINA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 123 CHINA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 124 CHINA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 125 CHINA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 126 CHINA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 127 CHINA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 128 CHINA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 129 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 130 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 131 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 132 INDIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 133 INDIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 134 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 135 INDIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 136 INDIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 137 INDIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 138 INDIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 139 INDIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 140 INDIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 141 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 142 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 143 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 144 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 145 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 146 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 147 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 148 INDIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 149 INDIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 150 INDIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 151 INDIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 152 INDIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 153 INDIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 154 INDIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 155 INDIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 156 INDIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 157 INDIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 158 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 159 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 160 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 161 JAPAN TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 162 JAPAN TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 163 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 164 JAPAN SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 165 JAPAN TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 166 JAPAN PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 167 JAPAN MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 168 JAPAN CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 169 JAPAN EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 170 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 171 AE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 172 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 173 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 174 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 175 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 176 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 177 JAPAN CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 178 JAPAN CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 179 JAPAN ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 180 JAPAN GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 181 JAPAN PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 182 JAPAN ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 183 JAPAN NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 184 JAPAN ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 185 JAPAN OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 186 JAPAN OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 187 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 188 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 189 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 190 AUSTRALIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 191 AUSTRALIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 192 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 193 AUSTRALIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 194 AUSTRALIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 195 AUSTRALIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 196 AUSTRALIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 197 AUSTRALIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 198 AUSTRALIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 199 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 200 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 201 ISREAL ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 202 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 203 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 204 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 205 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 206 AUSTRALIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 207 AUSTRALIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 208 AUSTRALIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 209 AUSTRALIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 210 AUSTRALIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 211 AUSTRALIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 212 AUSTRALIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 213 AUSTRALIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 214 AUSTRALIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 215 AUSTRALIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 216 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 217 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 218 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 219 SOUTH KOREA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 220 SOUTH KOREA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 221 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 222 SOUTH KOREA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 223 SOUTH KOREA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 224 SOUTH KOREA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 225 SOUTH KOREA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 226 SOUTH KOREA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 227 SOUTH KOREA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 228 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 229 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 230 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 231 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 232 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 233 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 234 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 235 SOUTH KOREA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 236 SOUTH KOREA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 237 SOUTH KOREA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 238 SOUTH KOREA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 239 SOUTH KOREA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 240 SOUTH KOREA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 241 SOUTH KOREA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 242 SOUTH KOREA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 243 SOUTH KOREA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 244 SOUTH KOREA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 245 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 246 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 247 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 248 SINGAPORE TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 249 SINGAPORE TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 250 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 251 SINGAPORE SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 252 SINGAPORE TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 253 SINGAPORE PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 254 SINGAPORE MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 255 SINGAPORE CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 256 SINGAPORE EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 257 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 258 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 259 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 260 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 261 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 262 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 263 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 264 SINGAPORE CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 265 SINGAPORE CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 266 SINGAPORE ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 267 SINGAPORE GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 268 SINGAPORE PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 269 SINGAPORE ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 270 SINGAPORE NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 271 SINGAPORE ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 272 SINGAPORE OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 273 SINGAPORE OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 274 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 275 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 276 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 277 MALAYSIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 278 MALAYSIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 279 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 280 MALAYSIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 281 MALAYSIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 282 MALAYSIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 283 MALAYSIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 284 MALAYSIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 285 MALAYSIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 286 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 287 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 288 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 289 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 290 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 291 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 292 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 293 MALAYSIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 294 MALAYSIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 295 MALAYSIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 296 MALAYSIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 297 MALAYSIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 298 MALAYSIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 299 MALAYSIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 300 MALAYSIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 301 MALAYSIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 302 MALAYSIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 303 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 304 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 305 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 306 THAILAND TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 307 THAILAND TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 308 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 309 THAILAND SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 310 THAILAND TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 311 THAILAND PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 312 THAILAND MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 313 THAILAND CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 314 THAILAND EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 315 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 316 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 317 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 318 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 319 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 320 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 321 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 322 THAILAND CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 323 THAILAND CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 324 THAILAND ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 325 THAILAND GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 326 THAILAND PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 327 THAILAND ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 328 THAILAND NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 329 THAILAND ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 330 THAILAND OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 331 THAILAND OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 332 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 333 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 334 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 335 INDONESIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 336 INDONESIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 337 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 338 INDONESIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 339 INDONESIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 340 INDONESIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 341 INDONESIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 342 INDONESIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 343 INDONESIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 344 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 345 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 346 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 347 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 348 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 349 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 350 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 351 INDONESIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 352 INDONESIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 353 INDONESIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 354 INDONESIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 355 INDONESIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 356 INDONESIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 357 INDONESIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 358 INDONESIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 359 INDONESIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 360 INDONESIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 361 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 362 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 363 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 364 PHILIPPINES TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 365 PHILIPPINES TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 366 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 367 PHILIPPINES SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 368 PHILIPPINES TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 369 PHILIPPINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 370 PHILIPPINES MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 371 PHILIPPINES CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 372 PHILIPPINES EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 373 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 374 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 375 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 376 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 377 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 378 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 379 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 380 PHILIPPINES CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 381 PHILIPPINES CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 382 PHILIPPINES ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 383 PHILIPPINES GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 384 PHILIPPINES PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 385 PHILIPPINES ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 386 PHILIPPINES NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 387 PHILIPPINES ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 388 PHILIPPINES OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 389 PHILIPPINES OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 390 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 391 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 392 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 393 VIETNAM TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 394 VIETNAM TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 395 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 396 VIETNAM SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 397 VIETNAM TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 398 VIETNAM PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 399 VIETNAM MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 400 VIETNAM CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 401 VIETNAM EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 402 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 403 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 404 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 405 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 406 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 407 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 408 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 409 VIETNAM CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 410 VIETNAM CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 411 VIETNAM ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 412 VIETNAM GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 413 VIETNAM PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 414 VIETNAM ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 415 VIETNAM NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 416 VIETNAM ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 417 VIETNAM OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 418 VIETNAM OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 419 REST OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

그림 목록

FIGURE 1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: MARKET TYPE OF MANUFACTURER COVERAGE GRID

FIGURE 11 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SEGMENTATION

FIGURE 12 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING IS DRIVING THE ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 SMALL MOLECULE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET

FIGURE 15 NUMBER OF PERSONS AGED 60 YEARS ACROSS SEVERAL REGIONS IN 2017 AND 2050

FIGURE 16 HEALTHCARE EXPENDITURE PER CAPITA

FIGURE 17 SHARE OF API MARKET OCCUPIED IN ASIA

FIGURE 18 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, 2021

FIGURE 19 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, 2017-2028 (USD MILLION)

FIGURE 20 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, CAGR (2021-2028)

FIGURE 21 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, LIFELINE CURVE

FIGURE 1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, 2021

FIGURE 2 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, 2017-2028 (USD MILLION)

FIGURE 3 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 4 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 5 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, 2021

FIGURE 6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, 2017-2028 (USD MILLION)

FIGURE 7 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, CAGR (2021-2028)

FIGURE 8 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, LIFELINE CURVE

FIGURE 9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, 2021

FIGURE 10 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, 2017-2028 (USD MILLION)

FIGURE 11 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, CAGR (2021-2028)

FIGURE 12 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, LIFELINE CURVE

FIGURE 13 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, 2021

FIGURE 14 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

FIGURE 15 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, CAGR (2021-2028)

FIGURE 16 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, LIFELINE CURVE

FIGURE 17 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, 2021

FIGURE 18 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, 2017-2028 (USD MILLION)

FIGURE 19 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, CAGR (2021-2028)

FIGURE 20 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, LIFELINE CURVE

FIGURE 21 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, 2021

FIGURE 22 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, 2017-2028 (USD MILLION)

FIGURE 23 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, CAGR (2021-2028)

FIGURE 24 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, LIFELINE CURVE

FIGURE 25 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, 2021

FIGURE 26 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, 2017-2028 (USD MILLION)

FIGURE 27 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, CAGR (2021-2028)

FIGURE 28 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, LIFELINE CURVE

FIGURE 29 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, 2021

FIGURE 30 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

FIGURE 31 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, CAGR (2021-2028)

FIGURE 32 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE

FIGURE 33 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SNAPSHOT (2020)

FIGURE 34 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY COUNTRY (2020)

FIGURE 35 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY COUNTRY (2021 & 2028)

FIGURE 36 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY COUNTRY (2020 & 2028)

FIGURE 37 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE (2021-2028)

FIGURE 38 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: COMPANY SHARE 2020 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Asia-Pacific active pharmaceutical ingredients (API) market is expected to grow at a CAGR of 7.5% during the forecast period of 2021 to 2028.
The future market of the Asia-Pacific active pharmaceutical ingredients (API) market is expected to reach USD 86,222.48 million by 2028.
The major players in the Asia-Pacific active pharmaceutical ingredients (API) market are Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi, GlaxoSmithKline plc., Aarti Industries Limited, Recipharm AB, Jubilant Pharmova Limited, LUPIN, Aurobindo Pharma, AbbVie Inc., AstraZeneca, Alkem Labs, Albemarle Corporation, Saneca Pharmaceuticals, Unichem Laboratories, Neuland Laboratories Ltd., Divi's Laboratories Limited., HIKAL Ltd., etc.
The countries covered in the Asia-Pacific active pharmaceutical ingredients (API) market are Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific.

관련 페이지 탐색

Banner